Should You Buy CVS Stock on the Dip?

CVS Health reported Q2 revenue of $106 billion, up 7.3% year over year, while adjusted EPS increased 43%. The company operates roughly 9,000 pharmacies, more than 1,000 clinics, a PBM serving about 87 million members, and an insurance business reaching over 35 million people. Shares recently traded near $95, with a forward P/E of 11 versus a five-year average of 10; one analyst rates the stock a buy with a $120 target. CVS also offers a 2.8% dividend yield, with its annual payout rising to $2.66 per share from $2.42 in 2023.

Analysis

The relevant question for CVS is not headline revenue growth but whether medical-cost trend and Medicare Advantage pricing are normalizing quickly enough to convert an apparently low earnings multiple into sustainable free cash flow. A modest improvement in the insurance benefit-cost ratio can drive disproportionate EPS upside because fixed corporate costs are high; conversely, another utilization or risk-adjustment miss would make the current valuation a value trap. The retail/PBM businesses provide cash-flow ballast, but reimbursement pressure and generic-drug deflation limit their ability to offset a renewed insurance-margin shortfall.

GLP-1 exposure is more ambiguous than the bullish framing implies. CVS Caremark can benefit from prescription volume and formulary-management fees, but broad obesity-drug coverage raises employer and health-plan drug costs before downstream reductions in cardiometabolic claims emerge, likely a multi-year lag. CVS is structurally better positioned than standalone pharmacies to capture adherence and care-management economics, yet PBM scrutiny could cap the multiple investors are willing to pay even if near-term earnings recover.

Near term, CVS is a guidance-execution trade rather than a catalyst-rich rerating story. The 1-3 month setup improves if management demonstrates sequential medical-cost improvement and holds 2027 Medicare Advantage economics; over 6-18 months, asset sales, lower leverage, and proof that Aetna can earn an acceptable return on capital would justify multiple expansion versus managed-care peers. The contrarian risk is that a low P/E already reflects durable regulatory and reimbursement discounting, not merely cyclical impairment.

Key Decisions for Investors

• Maintain CVS on a long watchlist; initiate only following an earnings report that raises or firmly reiterates full-year adjusted EPS and shows sequential improvement in the insurance medical-benefit ratio. Target a 10-15% rerating over 6-12 months; exit on a guidance cut or renewed utilization-cost deterioration.
• Express a cleaner recovery view via a small long CVS / short WBA pair over 3-6 months: CVS has diversified insurance and PBM earnings while WBA remains more exposed to retail pharmacy reimbursement and store rationalization. Review if the pair fails to outperform by 10% after the next two earnings cycles.
• Do not underwrite material GLP-1 upside until disclosed formulary economics, net drug-cost trend, and employer renewal retention verify that incremental scripts are profitable rather than a claims-cost headwind.
• Monitor CMS Medicare Advantage rate and risk-adjustment developments as the highest-impact external catalyst. Adverse policy or reimbursement changes would argue for avoiding CVS regardless of the nominal earnings multiple; favorable clarity could support adding ahead of the next annual enrollment cycle.